Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 3/20 | 0.39 |
| ▸ | CASP7 | P55210 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899094 | 0.84 | KDM4E (0.63) | ALDH1A1HSD17B10MAPK1RXFP1GLA | |
| SCHEMBL22191283 | 0.80 | ALDH1A1 (0.42) | ALDH1A1HSD17B10MAPK1RXFP1GLA | |
| SCHEMBL29352983 | 0.80 | ALDH1A1 (0.42) | ALDH1A1HSD17B10MAPK1RXFP1GLA | |
| SCHEMBL2019618 | 0.79 | PDE1B (0.43) | ALDH1A1HSD17B10MAPK1RXFP1GLA | |
| SCHEMBL3330739 | 0.77 | KDM4E (0.45) | ALDH1A1HSD17B10MAPK1RXFP1GLA | |
| SCHEMBL1897434 | 0.75 | PIK3CA (0.40) | ALDH1A1HSD17B10MAPK1RXFP1GLA | |
| SCHEMBL188690 | 0.73 | ALDH1A1 (0.71) | ALDH1A1HSD17B10MAPK1RXFP1GLA | |
| SCHEMBL1987257 | 0.73 | PIK3CA (0.74) | ALDH1A1HSD17B10MAPK1RXFP1GLA | |
| SCHEMBL5128256 | 0.72 | CYP1A2 (0.46) | ALDH1A1HSD17B10MAPK1RXFP1HPGD | |
| SCHEMBL1901293 | 0.72 | ALDH1A1 (0.44) | ALDH1A1HSD17B10GLAGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255162-A1 | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents | WARNER-LAMBERT COMPANY LLC | 2008-10-16 | — | — | US | disclosed |
| EP-1749004-B1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | WARNER LAMBERT CO (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1749004-A1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005105801-A1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255162-A1 | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents | TYMS, DPYD, TYMP | ALDH1A1 749/4885HSD17B10 4305/4885MAPK1 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.